Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib | Zendy

Susan Branford | Zendy; DongWook Kim | Zendy; Simona Soverini | Zendy; Md Ariful Haque | Zendy; Yaping Shou | Zendy; Richard C. Woodman | Zendy; Hagop M. Kantarjian | Zendy; Giovanni Martinelli | Zendy; Jerald P. Radich | Zendy; Giuseppe Saglio | Zendy; Andreas Hochhaus | Zendy; Timothy P. Hughes | Zendy; Martin C. Müller | Zendy

Open Access

Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib

Author(s) -

Susan Branford,

DongWook Kim,

Simona Soverini,

Md Ariful Haque,

Yaping Shou,

Richard C. Woodman,

Hagop M. Kantarjian,

Giovanni Martinelli,

Jerald P. Radich,

Giuseppe Saglio,

Andreas Hochhaus,

Timothy P. Hughes,

Martin C. Müller

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.40.5217

Subject(s) - cumulative incidence , nilotinib , medicine , imatinib , myeloid leukemia , imatinib mesylate , incidence (geometry) , oncology , gastroenterology , cohort , physics , optics

The association between initial molecular response and longer-term outcomes with nilotinib was examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research